Search results for: Health Policy and Regulation
Filter search results
From Efficacy to Cost-Effectiveness
1 May 1998
…of cost-effectiveness outcomes from efficacy data. There has been criticism of modelling, notably from the Food and Drug Administration (DDMAC, 1995) and the New England Journal of Medicine (Kassirer and Angel, 1994)….
Achieving World Class Outcomes in Cancer Treatment
1 July 2011
The speaker for the OHE’s 16th Annual Lecture was Sir Mike Richards, National Clinical Director for Cancer and End of Life Care in England’s Department of Health. In his presentation,…
Causes of Death: A Study of a Century of Change in England and Wales
1 October 2012
…between 1997 and 2007, mortality rates increased for diseases of the digestive system, including fibrosis and cirrhosis of the liver. According to the authors, “This may indicate that whereas, in…
Carer quality of life in HTA: from measurement to economic models
17 September 2026, 1:00pm
…dedicated Q&A throughout, this is a must-attend for anyone working at the intersection of HTA, economic modelling, and patient/carer-centred evidence. Ticket typePrice (VAT inclusive)Dates ApplicableRegistrationEarly Bird Concession (students, NHS/Healthcare Providers,…
Combination Therapies: A Step Forward to the Value Attribution Problem
4 January 2023
…delegates (both online and in-person) from industry and academia with strong health economic expertise. Ten different countries were represented, including Australia, the UK and other major European nations. Gavin Lewis,…
Professor Aidan Hollis wins first £40,000 OHE Policy Innovation Prize
25 January 2023
To celebrate 60 years, the Office of Health Economics (OHE) launched a prize to promote original thinking and solve critical problems in health economics. The inaugural winner, Professor Aidan Hollis,…
HTAi Asia Policy Forum Briefing Papers: Value and Affordability, Transferability, and Delivery of High Quality HTA for Decision Making
2 May 2017
…medical device companies with interest and expertise in Asia; invited experts; and the organisers, and are designed to promote in-depth, open and constructive exchange between these stakeholder groups. The OHE…
OHE Welcomes Patrick Holmes to the Board of Trustees
28 March 2022
…in New York and heads a team responsible for developing global health policy initiatives and evidence across a series of policy issues supporting Pfizer’s R&D-driven organization, including driving affordable patient…
New Drugs to Tackle Antimicrobial Resistance: EU Policy Options
1 October 2010
Antimicrobial resistance (AMR) to drugs, a natural and unavoidable consequence of treating infectious diseases, is a growing global public health threat. The EU Commission is to develop comprehensive proposals by…